HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Aspden, K. Articles by Williamson, A.-L. Search for Related Content PubMed PubMed Citation Articles by Aspden, K. Articles by Williamson, A.-L. Agricola Articles by Aspden, K. Articles by Williamson, A.-L.

Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector

¹ Division of Medical Virology, Department of Clinical Laboratory Science & Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory 7925, Cape Town, South Africa
² National Health Laboratory Service, University of Cape Town, Observatory 7925, Cape Town, South Africa

Correspondence
Anna-Lise Williamson (at Division of Medical Virology)
annalise{at}curie.uct.ac.za

Lumpy skin disease virus (LSDV), a capripoxvirus with a host range limited to ruminants, was evaluated as a replication-deficient vaccine vector for use in non-ruminant hosts. By using the rabies virus glycoprotein (RG) as a model antigen, it was demonstrated that recombinant LSDV encoding the rabies glycoprotein (rLSDV-RG) was able to express RG in both permissive (ruminant) and non-permissive (non-ruminant) cells. The recombinant LSDV, however, replicated to maturity only in permissive but not in non-permissive cells. Recombinant LSDV-RG was assessed for its ability to generate immunity against RG in non-ruminant hosts (rabbits and mice). Rabbits inoculated with rLSDV-RG produced rabies virus (RV) neutralizing antibodies at levels twofold higher than those reported by the WHO to be protective. BALB/c mice immunized with rLSDV-RG elicited levels of RV-specific cellular immunity (T-cell proliferation) comparable with those of mice immunized with a commercial inactivated rabies vaccine (Verorab; Pasteur Merieux). Most importantly, mice immunized with rLSDV-RG were protected from an aggressive intracranial rabies virus challenge.

This article has been cited by other articles:

				B. Pignolet, S. Boullier, J. Gelfi, M. Bozzetti, P. Russo, E. Foulon, G. Meyer, M. Delverdier, G. Foucras, and S. Bertagnoli Safety and immunogenicity of myxoma virus as a new viral vector for small ruminants J. Gen. Virol., June 1, 2008; 89(6): 1371 - 1379. [Abstract] [Full Text] [PDF]